首页 文献索引 SCI期刊 AI助手
首页 正文

Review ESMO open. 2023 Jun;8(3):101573. doi: 10.1016/j.esmoop.2023.101573 Q18.32025

MiRNA dysregulation underlying common pathways in type 2 diabetes and cancer development: an Italian Association of Medical Oncology (AIOM)/Italian Association of Medical Diabetologists (AMD)/Italian Society of Diabetology (SID)/Italian Society of Endocrinology (SIE)/Italian Society of Pharmacology (SIF) multidisciplinary critical view

二型糖尿病与癌症发病过程中的共同途径：微小核糖核酸失调：意大利肿瘤学协会/意大利医学糖尿病学会/意大利糖尿病学会/意大利内分泌学会/意大利药理学会多学科观点 翻译改进

A Natalicchio  1, M Montagnani  2, M Gallo  3, N Marrano  1, A Faggiano  4, M C Zatelli  5, R Mazzilli  4, A Argentiero  6, R Danesi  7, S D'Oronzo  8, S Fogli  7, D Giuffrida  9, S Gori  10, A Ragni  3, V Renzelli  11, A Russo  12, T Franchina  13, E Tuveri  14, L Sciacca  15, M Monami  16, G Cirino  17, G Di Cianni  18, A Colao  19, A Avogaro  20, S Cinieri  21, N Silvestris  13, F Giorgino  22

作者单位 +展开

作者单位

  • 1 Department of Precision and Regenerative Medicine and Ionian Area, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Bari, Italy.
  • 2 Department of Precision and Regenerative Medicine and Ionian Area, Section of Pharmacology, Medical School, University of Bari Aldo Moro, Bari, Italy.
  • 3 Endocrinology and Metabolic Diseases Unit, AO SS Antonio e Biagio e Cesare Arrigo of Alessandria, Alessandria, Italy.
  • 4 Endocrinology Unit, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, ENETS Center of Excellence, Sapienza University of Rome, Rome, Italy.
  • 5 Section of Endocrinology, Geriatrics, and Internal Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
  • 6 Medical Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
  • 7 Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • 8 Interdisciplinary Department of Medicine, University of Bari Aldo Moro, Bari, Italy.
  • 9 Department of Oncology, Istituto Oncologico del Mediterraneo, Viagrande, Catania, Italy.
  • 10 Oncologia Medica, IRCCS Ospedale Don Calabria-Sacro Cuore di Negrar, Verona, Italy.
  • 11 Diabetologist and Endocrinologist, Italian Association of Clinical Diabetologists, Rome, Italy.
  • 12 Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy.
  • 13 Medical Oncology Unit, Department of Human Pathology "G. Barresi", University of Messina, Messina, Italy.
  • 14 Diabetology, Endocrinology and Metabolic Diseases Service, ASL-Sulcis, Carbonia, Sardinia, Italy.
  • 15 Department of Clinical and Experimental Medicine, Endocrinology Section, University of Catania, Catania, Italy.
  • 16 Diabetology, Careggi Hospital and University of Florence, Firenze, Italy.
  • 17 Department of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Naples, Italy.
  • 18 Diabetes Unit, Livorno Hospital, Livorno, Italy.
  • 19 Endocrinology, Diabetology and Andrology Unit, Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy; UNESCO Chair, Education for Health and Sustainable Development, Federico II University, Naples, Italy.
  • 20 Department of Medicine, University of Padova, Padua, Italy.
  • 21 Medical Oncology Division and Breast Unit, Senatore Antonio Perrino Hospital, ASL Brindisi, Brindisi, Italy.
  • 22 Department of Precision and Regenerative Medicine and Ionian Area, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Bari, Italy. Electronic address: francesco.giorgino@uniba.it.

    • DOI: 10.1016/j.esmoop.2023.101573 PMID: 37263082

    摘要 Ai翻译

    Increasing evidence suggests that patients with diabetes, particularly type 2 diabetes (T2D), are characterized by an increased risk of developing different types of cancer, so cancer could be proposed as a new T2D-related complication. On the other hand, cancer may also increase the risk of developing new-onset diabetes, mainly caused by anticancer therapies. Hyperinsulinemia, hyperglycemia, and chronic inflammation typical of T2D could represent possible mechanisms involved in cancer development in diabetic patients. MicroRNAs (miRNAs) are a subset of non-coding RNAs, ⁓22 nucleotides in length, which control the post-transcriptional regulation of gene expression through both translational repression and messenger RNA degradation. Of note, miRNAs have multiple target genes and alteration of their expression has been reported in multiple diseases, including T2D and cancer. Accordingly, specific miRNA-regulated pathways are involved in the pathogenesis of both conditions. In this review, a panel of experts from the Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE), and Italian Society of Pharmacology (SIF) provide a critical view of the evidence about the involvement of miRNAs in the pathophysiology of both T2D and cancer, trying to identify the shared miRNA signature and pathways able to explain the strong correlation between the two conditions, as well as to envision new common pharmacological approaches.

    Keywords: cancer; miRNA-based drugs; miRNAs; type 2 diabetes.

    Keywords：type 2 diabetes; cancer development; miRNA dysregulation

    关键词：二型糖尿病; 癌症发生; 微小RNA失调

    Copyright © ESMO open. 中文内容为AI机器翻译，仅供参考！

    相关内容

    期刊名：Esmo open

    缩写：

    ISSN：N/A

    e-ISSN：2059-7029

    IF/分区：8.3/Q1

    文章目录 更多期刊信息

    全文链接
    官方链接
    PMC全文
    引文链接
    复制
    已复制！
    推荐内容
    MiRNA dysregulation underlying common pathways in type 2 diabetes and cancer development: an Italian Association of Medical Oncology (AIOM)/Italian Association of Medical Diabetologists (AMD)/Italian Society of Diabetology (SID)/Italian Society of Endocrinology (SIE)/Italian Society of Pharmacology (SIF) multidisciplinary critical view